ASH2L — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15004646	0.79	5/20
SCHEMBL15004656	0.79	5/20
SCHEMBL15004659	0.79	5/20
SCHEMBL15005695	0.79	5/20
SCHEMBL15004652	0.78	5/20
SCHEMBL15004651	0.77	5/20
SCHEMBL15004665	0.74	5/20
SCHEMBL15004653	0.73	5/20
SCHEMBL15005651	0.69	5/20
SCHEMBL15004655	0.65	5/20
SCHEMBL15004660	0.65	5/20
SCHEMBL15004662	0.65	5/20
SCHEMBL15004663	0.65	5/20
SCHEMBL15004664	0.65	5/20
SCHEMBL15005648	0.65	5/20
SCHEMBL15005689	0.60	5/20
SCHEMBL15005650	0.56	5/20
SCHEMBL15005676	0.55	5/20
SCHEMBL9940650	0.43	5/20
SCHEMBL469241	0.76	4/20

Clinical trials — most relevant to ASH2L by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment	PHASE2/PHASE3	RECRUITING
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors	PHASE2	RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
The Efficacy of Allo-HSCT in ND HR-CBF-AML	nan	RECRUITING
Clinical and Genomic Registry of MDS in Asia	nan	UNKNOWN
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED
Mechanisms of Immune Deficiency	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ASH2L binder may also engage these)

Protein	Name	Similarity
Q91X20	—	1.000	Q91X20 →
A0AA41T7Z4	—	1.000	A0AA41T7Z4 →
Q94545	—	0.999	Q94545 →
G5EFZ3	—	0.995	G5EFZ3 →
P25799	—	0.994	P25799 →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.993	landscape →
KAT8	Histone acetyltransferase KAT8	0.993	landscape →
KDM5B	Lysine-specific demethylase 5B	0.993	landscape →
Q8WUB8	—	0.993	Q8WUB8 →
P69566	—	0.992	P69566 →
Q5XI06	—	0.992	Q5XI06 →
Q7PZD5	—	0.992	Q7PZD5 →
A1L252	—	0.992	A1L252 →
Q6VN19	—	0.992	Q6VN19 →
Q6ZPS6	—	0.991	Q6ZPS6 →
SMARCC1	SWI/SNF complex subunit SMARCC1	0.991	landscape →
KDM5D	Lysine-specific demethylase 5D	0.991	landscape →
P43125	—	0.991	P43125 →
P97496	—	0.991	P97496 →
B2GUZ1	—	0.991	B2GUZ1 →
D3YWQ0	—	0.991	D3YWQ0 →
Q8BX57	—	0.991	Q8BX57 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.990	landscape →
KDM1A	Lysine-specific histone demethylase 1A	0.990	landscape →
Q8BMD7	—	0.990	Q8BMD7 →
D3ZA12	—	0.990	D3ZA12 →
P41230	—	0.990	P41230 →
E7EZF3	—	0.990	E7EZF3 →
Q7TPK1	—	0.990	Q7TPK1 →
B4P6P7	—	0.990	B4P6P7 →